Table 1: (a) Demographic, clinical, and pathological manifestations of patients with CIK cells treatment. (b) Demographic, clinical, and pathological manifestations of patients without CIK cells treatment. (c) Comparison of the Motzer Criteria Factors between two groups.
(a)

CaseAge/sexNidusPathologic stage before Nx (TNM)Location of metastasesDisease state before CIK cell treatmentCIK cyclesDisease state after CIK cell treatmentDisease state by the end of followupPFS (month)OS (month)

UPN 169/MLeftT1N0M0CR4CRCR3131
UPN 243/MRightT1N0M0CR4CRCR4242
UPN 360/MLeftT1N0M0CR4CRCR3737
UPN 453/MLeftT2N0M1LungPD8PRSD1728
UPN 561/MLeftT1N0M0CR4CRCR4040
UPN 657/MRightT2N0M1LungPD8PRSD3841
UPN 779/FLeftT2N1M0Retroperitoneal lymph nodesPD8SDSD1226
UPN 850/MRightT1N0M0CR5CRCR4040
UPN 963/MRightT2N0M0CR4CRCR3232
UPN 1047/MLeftT1N0M1Brain (left
temporal lobe)
PD12SDSD3333

RCC: renal cell carcinoma; CIK: cytokine-induced killer; TNM: tumornodemetastasis.
(b)

CaseAge/sexNidusPathologic stage before Nx (TNM)Location of metastases at the beginning of followupDisease state at the beginning of followupTreatment protocolsDisease state after treatmentDisease state by the end of followupPFS (month)OS (month)

UPN 11*64/MRightT1N0M0CRPartial left nephrectomyCRCR2236
UPN 1245/FLeftT1N0M0CRCR3232
UPN 1341/MLeftT1N0M1LungPRChemotherapy + targeted therapySDPD730
UPN 1477/MRightT1N1M0Retroperitoneal lymph nodesSDIFN- + IL-2PRSD1138
UPN 1527/MLeftT1N0M0CRCR4040
UPN 1666/MLeftT1N0M1Cervical vertebraPDChemotherapy + radiotherapySDPD1235
UPN 1760/MRightT2N0M0CRChemotherapyPRSD1936
UPN 1845/MLeftT1N0M0CRCR2929
UPN 1965/FLeftT2N0M1Right adrenal glandPRChemotherapyPRSD1632
UPN 2046/MRightT1N0M0CRCR2828

UPN 11: the patient got left renal metastasis during the course of followup and got CR again after partial left nephrectomy till the end of followup.
(c)

FactorsGroup 1Group 2

Karnofsky performance status (KPS) ( , %)
 80–10067
 60–8043
Corrected calcium (mmol/L) 0.926
LDH level (U/L) 0.893
Hemoglobin level (g/L) 0.634
Time from diagnosis to systemic radical nephrectomy ( 1 year) ( , %)10 (100%)10 (100%)

Group 1: CIK cells treatment group; group 2: control group.
; there are no statistical significant differences between two groups.